System for evaluating a pathological stage of prostate cancer

US9779213B2 · kind B2 · utility

Assignee

• FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · PT

Inventors

• Michael Donovan · Boston, US
• Faisal Khan · Fishkill, US
• Jason Alter · Stamford, US
• Gerardo Fernandez · New York, US
• Ricardo Mesa-Tejada · Pleasantville, US
• Douglas H. Powell · Bronxville, US
• Valentina Bayer Zubek · Yonkers, US
• Stefan Hamann · Yonkers, US
• Carlos Cordon-Cardo · New York, US
• Jose Costa · Ottawa, CA

Key dates

• Filing date: Aug 28, 2009
• Grant date: Oct 3, 2017
• Expiry date: Aug 3, 2031

Classification

• Technology area (CPC G): Physics
• CPC primary: G16H50/70
• WIPO field: Medical technology
• WIPO sector: Instruments

Abstract

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.